Toronto Dominion Bank Has $6.50 Million Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Toronto Dominion Bank raised its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 5.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,696 shares of the medical device company's stock after buying an additional 3,924 shares during the quarter. Toronto Dominion Bank's holdings in Cooper Companies were worth $6,499,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in COO. Byrne Asset Management LLC purchased a new position in Cooper Companies during the 4th quarter valued at about $33,000. OFI Invest Asset Management acquired a new stake in Cooper Companies during the fourth quarter valued at $34,000. New Age Alpha Advisors LLC purchased a new position in Cooper Companies in the fourth quarter valued at about $38,000. Covestor Ltd grew its stake in Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, Atala Financial Inc acquired a new position in Cooper Companies in the 4th quarter worth about $51,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Stock Performance

Cooper Companies stock traded down $0.05 on Tuesday, reaching $66.95. 1,029,997 shares of the stock were exchanged, compared to its average volume of 1,545,527. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a twelve month low of $65.06 and a twelve month high of $112.38. The firm has a fifty day moving average price of $79.48 and a two-hundred day moving average price of $88.06. The stock has a market cap of $13.39 billion, a PE ratio of 34.33, a PEG ratio of 2.25 and a beta of 1.08.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.03. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $995.12 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm's revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.85 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus reduced their price target on Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a report on Friday, March 7th. Robert W. Baird reduced their target price on shares of Cooper Companies from $107.00 to $97.00 and set an "outperform" rating for the company in a research note on Friday. JPMorgan Chase & Co. restated a "neutral" rating and set a $76.00 price target (down previously from $110.00) on shares of Cooper Companies in a research note on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research note on Thursday, May 22nd. Finally, BNP Paribas raised shares of Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Cooper Companies presently has an average rating of "Moderate Buy" and an average price target of $100.38.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.